One R.I. man’s battle with Stage 4 colon cancer

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results

Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team

Dragonfly Therapeutics Announces the Publication of Preclinical Data

Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine

Dr. Joseph E. Eid joins Dragonfly Therapeutics as President of R&D

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engage

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Dragonfly Therapeutics Expands Clinical Leadership Team

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Merck and Dragonfly, Together Again

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

Merck hits 'go' on a second Dragonfly drug

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer